Skip to content
Search

Latest Stories

Christie & Co to manage sale of 44 Boots pharmacies

Boots UK has confirmed the sale of 44 pharmacies located across England and Wales and has appointed specialist property adviser Christie & Co to manage the sale.

This is part of the high street chain’s plan to consolidate or close a total of 200 pharmacies by the end of 2020.


Tracey Clements, Chief Operating Officer, Boots UK said, “We very much hope that these pharmacies continue to grow under new ownership. We are sure they will provide a fantastic opportunity for talented pharmacists to create a great local business.”

“The decision to sell or close a pharmacy is never easy, but we are continuing to invest in our wider store network by making our retail, pharmacy and online offer even more differentiated and personalised, with the best brands at the best value,” Clements said.

All sales are planned by May 2020 and the pharma chain called on “first-time buyers and independent pharmacists to buy a pharmacy previously run by Boots”.

“We are delighted to have been appointed by Boots UK to market 44 pharmacies by way of asset sales," said Tony Evans, Head of Pharmacy at Christie & Co.

"With dispensing volumes varying from 1,100 to in excess of 9,000 items per month, the pharmacies occupy either community, high street or health centre environments. The pharmacies offer a tremendous opportunity for first-time buyers and existing independent contractors, as well as regional multiple operators, to acquire corporately-owned pharmacies that are rarely available on the open market, as a result of which we anticipate that strong interest will be generated,” Evans added.

In its fiscal 2020 first-quarter results, Walgreens Boots Alliance (WBA), the parent company of Boots UK, again reported a decline in profits and confirmed the closure of 28 pharmacies.

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less